CytoDyn's leronlimab shows encouraging action in stroke

• CytoDyn (OTCQB:CYDY) announces promising early responses in two patients recovering from strokes.
• One patient experienced improved sensations in his body and face and the other experienced improvement in her partial paralysis.
• Chairman, CMO and Head of Business Development Scott Kelly, M.D., says, “We are encouraged by leronlimab’s potential to help patients recover from stroke and traumatic brain injury. Independent research has concluded that CCR5 is upregulated in neurons after stroke, blocking CCR5 induces motor recovery after stroke and CCR5 antagonism may enhance learning, memory, and plasticity. CCR5 is rapidly becoming an important target for neural repair in stroke and traumatic brain injury. Our recent data shows that leronlimab crosses the blood-brain barrier with 70-75% receptor occupancy of the CCR5 receptors in the brain (Macaque model) which is encouraging for the potential to enhance recovery in stroke and traumatic brain injury."
• The company says leronlimab inhibits (binds to) a protein on the surface of certain immune cells called Cysteine-Cysteine Chemokine Receptor 5 (CCR5), which play a key role in modulating immune cell trafficking in sites of inflammation, so it may have potential to treat COVID-19 (and other diseases and conditions).
• https://seekingalpha.com/news/3625596-cytodyns-leronlimab-shows-encouraging-action-in-stroke-patients